#4364
Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma
Introduction:
Radiolabelled therapy with meta-iodobenzguanine (MIBG) and chemotherapy with a combination of cyclophosphamide, vincristine, and dacarbazine can help manage patients with metastatic pheochromocytoma and paraganglioma (mPPGL). The phase II FIRSTMAPPP study supports the use of the tyrosine kinase inhibitor sunitinib in these malignancies, with median progression-free survival values of 8.9 versus 3.6 months and overall response rates of 31% versus 8% for sunitinib versus placebo. The median duration of sunitinib therapy was 11 months. Concurrent with this study, we launched a single-arm trial to examine the activity of a similar tyrosine kinase inhibitor, axitinib.
Conference:
Presenting Author:
Del Rivero J
Authors:
Del Rivero J,
Fojo T,
Edgerly M,
Pacak K,
Figg W,
Keywords:
PPGL,
pheochromocytoma,
paraganglioma,
axitinib,
TKI,
tyrosinase kinase inhibitors,
#3736
Risk of complications after biopsy in pheochromocytoma and paraganglioma
Introduction:
Core needle biopsy (CNB) has been used with caution in pheochromocytoma and paraganglioma (PPGL) due to concerns about catecholamine-related complications. While it is unclear what scientific evidence supports this claim, it has limited the acquisition of biological samples for diagnostic purposes and research, especially in metastatic PPGL.
Conference:
Presenting Author:
Zhang L
Authors:
Zhang L,
Åkerström T,
Mollazadegan K,
Beuschlein F,
Pacak K,
Keywords:
Pheochromocytoma,
paraganglioma,
core needle biopsy,
diagnosis,
risk,
#944
Pheochromocytoma and Paraganglioma in Pediatric Age
Introduction:
Pheochromocytoma (PHE) and paraganglioma (PGL) are rare tumors of the adrenal medulla and extra-adrenal sympathetic chromaffin tissue. Nearly 30% of them are familiar or associated with genetic syndromes (VHL, MEN2, NF1, SDH mutation, Pacak-Zhuang). Only 20% PHE occur before 20 years of age. Incidence of pediatric PHE is 0.3:1 million.
Conference:
11th Annual ENETSConcerence (2014)
Presenting Author:
Bajciova V
Authors:
Bajciova V,
Kren L,
Vicha A,
Keywords:
pheochromocytoma,
paraganglioma,
pediatric age,
